Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mentoring | 1 | 2023 | 77 | 0.740 |
Why?
|
| Multiple Myeloma | 4 | 2021 | 201 | 0.540 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 2 | 2025 | 8 | 0.460 |
Why?
|
| Internship and Residency | 2 | 2023 | 1164 | 0.420 |
Why?
|
| Early Detection of Cancer | 3 | 2024 | 398 | 0.360 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2024 | 253 | 0.340 |
Why?
|
| Emergency Medical Services | 2 | 2022 | 399 | 0.300 |
Why?
|
| Bayes Theorem | 2 | 2024 | 284 | 0.250 |
Why?
|
| Beekeeping | 1 | 2025 | 1 | 0.240 |
Why?
|
| Colony Collapse | 1 | 2025 | 1 | 0.240 |
Why?
|
| Prostate-Specific Antigen | 2 | 2018 | 233 | 0.240 |
Why?
|
| Hydrogen Sulfide | 1 | 2024 | 11 | 0.220 |
Why?
|
| Varenicline | 1 | 2024 | 12 | 0.220 |
Why?
|
| Models, Statistical | 2 | 2024 | 465 | 0.220 |
Why?
|
| Golgi Apparatus | 1 | 2024 | 90 | 0.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 1306 | 0.220 |
Why?
|
| Prostatic Neoplasms | 3 | 2018 | 1386 | 0.210 |
Why?
|
| Camping | 1 | 2004 | 14 | 0.210 |
Why?
|
| Mass Screening | 3 | 2024 | 801 | 0.200 |
Why?
|
| Smoking Cessation | 1 | 2024 | 181 | 0.200 |
Why?
|
| Age of Onset | 1 | 2024 | 609 | 0.190 |
Why?
|
| Faculty | 1 | 2023 | 92 | 0.190 |
Why?
|
| Papillomavirus Vaccines | 1 | 2024 | 110 | 0.190 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2025 | 911 | 0.190 |
Why?
|
| Oligopeptides | 2 | 2021 | 113 | 0.190 |
Why?
|
| Advance Care Planning | 1 | 2022 | 40 | 0.190 |
Why?
|
| Breast Neoplasms | 3 | 2024 | 2586 | 0.190 |
Why?
|
| Communication | 2 | 2023 | 511 | 0.180 |
Why?
|
| Smoldering Multiple Myeloma | 1 | 2021 | 3 | 0.180 |
Why?
|
| Maternal-Fetal Relations | 1 | 2021 | 17 | 0.180 |
Why?
|
| Parturition | 1 | 2021 | 66 | 0.170 |
Why?
|
| Dexamethasone | 2 | 2021 | 263 | 0.170 |
Why?
|
| Indazoles | 1 | 2020 | 28 | 0.170 |
Why?
|
| Computer Simulation | 1 | 2024 | 660 | 0.170 |
Why?
|
| Software | 1 | 2025 | 711 | 0.170 |
Why?
|
| Graft vs Host Disease | 1 | 2026 | 625 | 0.170 |
Why?
|
| Genome-Wide Association Study | 2 | 2025 | 1721 | 0.170 |
Why?
|
| Deoxycytidine | 1 | 2020 | 81 | 0.160 |
Why?
|
| Curriculum | 2 | 2023 | 754 | 0.160 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 622 | 0.160 |
Why?
|
| Vagina | 1 | 2021 | 201 | 0.160 |
Why?
|
| Sequence Analysis, DNA | 1 | 2025 | 1738 | 0.160 |
Why?
|
| Papillomavirus Infections | 1 | 2024 | 386 | 0.150 |
Why?
|
| Football | 1 | 2019 | 33 | 0.150 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2021 | 229 | 0.150 |
Why?
|
| Humans | 27 | 2026 | 125910 | 0.150 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2020 | 128 | 0.150 |
Why?
|
| Substance-Related Disorders | 1 | 2023 | 483 | 0.150 |
Why?
|
| Sulfonamides | 1 | 2020 | 270 | 0.150 |
Why?
|
| Aged | 13 | 2024 | 20039 | 0.150 |
Why?
|
| Heart Conduction System | 1 | 2019 | 151 | 0.140 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 129 | 0.140 |
Why?
|
| Teaching Rounds | 1 | 2018 | 30 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2024 | 621 | 0.140 |
Why?
|
| Adaptation, Physiological | 1 | 2019 | 257 | 0.140 |
Why?
|
| Pyrimidines | 1 | 2020 | 391 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2026 | 1158 | 0.130 |
Why?
|
| Interprofessional Relations | 1 | 2018 | 153 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 542 | 0.130 |
Why?
|
| Biomarkers | 1 | 2026 | 3138 | 0.130 |
Why?
|
| Microbiota | 1 | 2021 | 429 | 0.120 |
Why?
|
| Lymphoma, Follicular | 1 | 2016 | 25 | 0.120 |
Why?
|
| Parents | 1 | 2023 | 1068 | 0.120 |
Why?
|
| Middle Aged | 12 | 2024 | 27336 | 0.120 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 1703 | 0.120 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2016 | 74 | 0.120 |
Why?
|
| Simulation Training | 1 | 2018 | 163 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 2744 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2025 | 3249 | 0.110 |
Why?
|
| Bone Marrow | 1 | 2016 | 304 | 0.110 |
Why?
|
| Radiotherapy | 1 | 2015 | 124 | 0.110 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2016 | 148 | 0.110 |
Why?
|
| Medical Records | 1 | 2015 | 177 | 0.110 |
Why?
|
| Adult | 10 | 2026 | 30254 | 0.100 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 793 | 0.100 |
Why?
|
| Female | 15 | 2026 | 67899 | 0.100 |
Why?
|
| Hodgkin Disease | 1 | 2016 | 291 | 0.100 |
Why?
|
| Male | 14 | 2026 | 62073 | 0.100 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 6581 | 0.090 |
Why?
|
| Genetic Variation | 1 | 2019 | 1520 | 0.090 |
Why?
|
| Atrial Fibrillation | 1 | 2019 | 694 | 0.090 |
Why?
|
| Young Adult | 5 | 2026 | 9588 | 0.090 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 1570 | 0.090 |
Why?
|
| Child | 3 | 2026 | 25060 | 0.080 |
Why?
|
| Pediatrics | 1 | 2018 | 1205 | 0.070 |
Why?
|
| Surveys and Questionnaires | 3 | 2025 | 3887 | 0.070 |
Why?
|
| Transcriptome | 2 | 2025 | 1064 | 0.060 |
Why?
|
| United States | 4 | 2025 | 11156 | 0.060 |
Why?
|
| Adolescent | 4 | 2026 | 19934 | 0.060 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2026 | 19 | 0.060 |
Why?
|
| United Kingdom | 2 | 2018 | 231 | 0.060 |
Why?
|
| Varroidae | 1 | 2025 | 2 | 0.060 |
Why?
|
| Bees | 1 | 2025 | 53 | 0.060 |
Why?
|
| Pandemics | 2 | 2024 | 1125 | 0.060 |
Why?
|
| Cystathionine beta-Synthase | 1 | 2024 | 14 | 0.060 |
Why?
|
| Michigan | 1 | 2004 | 45 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2026 | 639 | 0.050 |
Why?
|
| Binomial Distribution | 1 | 2023 | 5 | 0.050 |
Why?
|
| Utilization Review | 1 | 2004 | 39 | 0.050 |
Why?
|
| Kentucky | 1 | 2023 | 27 | 0.050 |
Why?
|
| Cause of Death | 2 | 2016 | 466 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 3652 | 0.050 |
Why?
|
| Stress, Physiological | 1 | 2024 | 256 | 0.050 |
Why?
|
| Chromatin | 1 | 2025 | 488 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2024 | 950 | 0.050 |
Why?
|
| Nursing Homes | 1 | 2022 | 88 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2026 | 1179 | 0.040 |
Why?
|
| Risk Factors | 2 | 2026 | 10355 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 2034 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2026 | 6167 | 0.040 |
Why?
|
| Computational Biology | 1 | 2025 | 839 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 1421 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 323 | 0.040 |
Why?
|
| Age Factors | 1 | 2026 | 2763 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2024 | 737 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 5091 | 0.040 |
Why?
|
| Animals | 3 | 2025 | 33172 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2022 | 648 | 0.040 |
Why?
|
| Vaccination | 1 | 2024 | 1001 | 0.040 |
Why?
|
| Genotype | 1 | 2024 | 2599 | 0.040 |
Why?
|
| Cesarean Section | 1 | 2021 | 424 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2018 | 132 | 0.040 |
Why?
|
| Animals, Newborn | 1 | 2021 | 1014 | 0.040 |
Why?
|
| Remission Induction | 1 | 2018 | 298 | 0.030 |
Why?
|
| Professional-Family Relations | 1 | 2018 | 95 | 0.030 |
Why?
|
| Focus Groups | 1 | 2018 | 211 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 3465 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2019 | 739 | 0.030 |
Why?
|
| Age Distribution | 1 | 2018 | 415 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 2019 | 348 | 0.030 |
Why?
|
| Algorithms | 1 | 2023 | 1635 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 1383 | 0.030 |
Why?
|
| Social Class | 1 | 2018 | 198 | 0.030 |
Why?
|
| Death Certificates | 1 | 2016 | 11 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2018 | 377 | 0.030 |
Why?
|
| Mice | 2 | 2024 | 17577 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2004 | 1018 | 0.030 |
Why?
|
| Incidence | 1 | 2023 | 3192 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2016 | 120 | 0.030 |
Why?
|
| South Carolina | 1 | 2015 | 8 | 0.030 |
Why?
|
| General Practitioners | 1 | 2015 | 17 | 0.030 |
Why?
|
| Mastectomy | 1 | 2015 | 73 | 0.030 |
Why?
|
| Phenotype | 1 | 2024 | 4298 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 226 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 770 | 0.030 |
Why?
|
| Time Factors | 1 | 2004 | 6026 | 0.030 |
Why?
|
| Prostate | 1 | 2016 | 405 | 0.030 |
Why?
|
| Brain | 1 | 2025 | 3019 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 1004 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 681 | 0.020 |
Why?
|
| Biopsy | 1 | 2016 | 1219 | 0.020 |
Why?
|
| Prevalence | 1 | 2019 | 2566 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 4503 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2018 | 673 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 1236 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 527 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 867 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2018 | 768 | 0.020 |
Why?
|
| Research Design | 1 | 2015 | 686 | 0.020 |
Why?
|
| Infant | 1 | 2026 | 12776 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2026 | 14341 | 0.020 |
Why?
|
| Pregnancy | 1 | 2021 | 7390 | 0.020 |
Why?
|
| Mutation | 1 | 2019 | 5920 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2018 | 12354 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2016 | 16778 | 0.010 |
Why?
|